Lenalidomide Teva Uk (Lenalidomide)

• Lenalidomide is an immunomodulatory agent used in the treatment of hematologic malignancies.
• Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality.
• Mantle Cell Lymphoma: contributes to disease control in patients with relapsed or refractory mantle‑cell lymphoma.

• Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to modulation of cytokine production, enhancement of T‑cell and natural killer cell activity, inhibition of angiogenesis, and direct anti‑tumor effects in malignant plasma cells.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.
• Nausea: feeling of sickness often accompanied by vomiting.
• Rash: mild skin eruptions or itching.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly reduced neutrophil count increasing infection risk.
• Secondary primary malignancies: emergence of new cancers unrelated to original disease.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.

When prescribing Lenalidomide, clinicians should consider several safety precautions.

• Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception.
• Thrombosis risk: assess for clotting risk and consider prophylactic anticoagulation.
• Renal impairment: adjust monitoring in patients with reduced kidney function.
• Hematologic monitoring: perform regular blood counts to detect neutropenia or anemia.
• Infection vigilance: monitor for signs of infection due to immunosuppression.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lenalidomide has known drug interactions that may require dose adjustment or monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce lenalidomide exposure (e.g., rifampin).
• Anticoagulants: increased risk of bleeding when combined with warfarin or DOACs.

Moderate Interactions (Monitor Closely)

• Immunosuppressants: may enhance infection risk (e.g., cyclosporine).
• Vaccines: live vaccines may be less effective; avoid during therapy.
• NSAIDs: concurrent use may increase risk of renal toxicity.